Rodríguez José E, Campbell Kendall M
Department of Family Medicine and Rural Health, The Center for Underrepresented Minorities in Academic Medicine, Florida State University College of Medicine, 1115 West Call Street, #3210 M, Tallahassee, FL 32306, USA.
Department of Family Medicine and Rural Health, The Center for Underrepresented Minorities in Academic Medicine, Florida State University College of Medicine, 1115 West Call Street, #3210 N, Tallahassee, FL 32306, USA.
Prim Care. 2016 Mar;43(1):61-7, viii. doi: 10.1016/j.pop.2015.08.011. Epub 2016 Jan 12.
Medications for obesity management can be divided into 4 groups: antidepressants (naltrexone/bupropion), stimulants (phentermine, phendimetrazine, diethylpropion, phentermine/topiramate), fat blockers (orlistat), and diabetes medications (liraglutide). Each group has specific therapeutic effects, adverse effects, and costs. Two medications are indicated for long-term use in obesity: lorcaserin and orlistat. Other available medications are for short-term use. High cost makes many of these medications inaccessible for underserved and poor patients. Because of misuse potential, many obesity medications are also classified as controlled substances. There are no medications currently approved for use in pregnant or lactating women.
用于肥胖管理的药物可分为4类:抗抑郁药(纳曲酮/安非他酮)、兴奋剂(苯丁胺、芬特明、二乙丙胺苯丙酮、苯丁胺/托吡酯)、脂肪阻滞剂(奥利司他)和糖尿病药物(利拉鲁肽)。每类药物都有特定的治疗效果、不良反应和成本。有两种药物被批准用于肥胖的长期治疗:氯卡色林和奥利司他。其他可用药物用于短期治疗。高昂的成本使许多此类药物无法提供给医疗服务不足的患者和贫困患者。由于存在滥用的可能性,许多肥胖药物也被列为管制药品。目前没有药物被批准用于孕妇或哺乳期妇女。